Nimotuzumab Combined With Concurrent Curative Radiotherapy and S‐1 in 75 Years and Older Patients With Stage II ‐ IVB Esophageal Squamous Cell Carcinoma: A Phase II Study

Documenti analoghi

• Real‐World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy‐Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
  di: Jingze Yan, et al.
  Pubblicazione: (2025)
• Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First‐Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study
  di: Xiaoyou Li, et al.
  Pubblicazione: (2025)
• Consolidation Chemotherapy Provided Survival Benefit for Esophageal Squamous Cell Carcinoma Patients Who Underwent Concurrent Chemoradiotherapy Lower Than 60 Gy
  di: Hualei Zhang, et al.
  Pubblicazione: (2025)
• Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients
  di: Kotaro Sugawara, et al.
  Pubblicazione: (2025)
• Lymph Node Metastasis for pN+ Superficial Esophageal Squamous Cell Carcinoma
  di: Yafan Yang, et al.
  Pubblicazione: (2025)